Ascendis Pharma A/S (ASND)

270.56USD -0.21% (-0.56)

Over 1M: +5.9%

Style
Area Line Line with markers Steps Candles Hollow candles Bars

Candles and bars need the day’s open, high and low, and need room to be drawn in: past about a year of trading a body is thinner than a hairline, so those three offer the longest window that fits instead.

250 260 270
7 Aug 12 Aug 17 Aug 20 Aug 25 Aug 28 Aug 2 Sep

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q1 '25 — Revenue: 101M Q1 '25 — Gross Profit: 83.4M Q1 '25 — Operating Cash Flow: -14.3M Q2 '25 — Revenue: 158M Q2 '25 — Gross Profit: 126.6M Q2 '25 — Operating Cash Flow: -7.3M Q3 '25 — Revenue: 213.6M Q3 '25 — Gross Profit: 191.3M Q3 '25 — Operating Cash Flow: 2.2M Q4 '25 — Revenue: 247.5M Q4 '25 — Gross Profit: 223.9M Q4 '25 — Operating Cash Flow: 73.4M 0 60M 120M 180M 240M 300M
Q1 '25 Q2 '25 Q3 '25 Q4 '25
Revenue Gross Profit Operating Cash Flow

How it scores

For a valuation multiple, the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

1.3
SBC / sales 16.1%
OE margin -8.6%
Oper. margin -18.9%
ROIC -20.6%
Accruals -21.6%
Gross margin 86.8%
FCF margin 7.5%
OCF margin 7.5%
EBITDA margin -16.5%
Profit margin -31.7%
ROA -17.5%
ROCE -58.4%
Capex / sales —
OCF / EBIT —
ROE —

5 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

1.5
EV/Sales 21.1×
EV/OE -243.5×
FCF yield 0.37%
P/C 23.5×
EV/GP 24.3×
Div. yield —
EV/EBIT —
Fwd P/E —
P/B —
P/E —
PEG —

2 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

0.5
RPO / sales —
RPO growth —
Segment HHI —

0 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

1.2
ND/EBITDA -0.045
Interest cover -0.66×
Cash / Debt 0.47×
Quick ratio 0.76×
Debt payback 12.7 yr
Cash runway —
Debt / Eq —
Equity / Assets —
F-score —
Net debt / Eq —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

10.0
Sales/sh Y/Y +89.2%
Sales Q/Q +42.3%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —
Sales CAGR 4Y —

1 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.